PARIS, FRANCE, February 28, 2024 – In the exciting context of effective new Alzheimer’s disease treatments, Qynapse are pleased to present our work at the upcoming AD/PD 2024 addressing the need for accurate standardized quantification of amyloid PET with QyScore’s automated pipeline for Centiloid quantification.
Qynapse poster presentation at AD/PD 2024
Abstract Title: an automated pipeline for Centiloid quantification of amyloid-β using multiple 11C-PIB-PET and 18F- PET tracers
Poster Shift 1: Wednesday, March 6 ,2024 – Poster Board Number: 0189
Presenting author: Elizabeth Gordon, Ph.D (Qynapse)
Dr Gordon will be present on-site to discuss the scientific results as well as potential commercial opportunity to implement its AI-powered neuroimaging software platform either in clinical routine or clinical trials. To contact her ahead of the event: via email at egordon@qynapse.com or on linkdin
About Qynapse: Qynapse Inc. is a medical technology company commercializing an AI-powered and proprietary neuroimaging software platform, creating the potential for earlier clinical precision on the frontlines of CNS disease. Qynapse’s flagship solution, QyScore®, FDA-Cleared and CE-Marked, adds the potential for more precise and objective brain scan analysis. Qynapse is headquartered in France with offices in the US Canada. www.qynapse.com